Clinical characteristics and outcomes of familial and idiopathic dilated cardiomyopathy in Cape Town: A comparative study of 120 cases followed up over 14 years

South African Medical Journal

Volumn 101, Issue 6, 2011, Pages 399-404

  Ntusi, Ntobeko B A ^a   Badri, Motasim ^b   Gumedze, Freedom ^c   Wonkam, Ambroise ^a   Mayosi, Bongani M ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DRUG MONITORING; ELECTROCARDIOGRAM; FAMILIAL DISEASE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PREVALENCE; Q WAVE; RETROSPECTIVE STUDY; SOUTH AFRICA; T WAVE INVERSION;

ADULT; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DIGOXIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; RETROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 79958022148     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29:270-276.
2. Ntusi NBA, Mayosi BM. Epidemiology of heart failure in sub-Saharan Africa. Exp Rev Cardiovasc Ther 2009;7:169-180.
3. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005;112:3577-3583.
4. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008;371:915-922.
5. Freers J, Hakim J, Mayanja-Kizza H, Parry E. The heart. In: Parry E, Godfrey R, Mabey D, Gill G, eds. Principles of Medicine in Africa. 3rd ed. Cambridge, UK: Cambridge University Press, 2004:837-886.
6. Sliwa K, Forster O, Libhaber E, Fett JD, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006;27(4):441-446.
7. Ntusi NBA, Wonkam A, Shaboodien G, Badri M, Mayosi BM. Frequency and clinical genetics of familial dilated cardiomyopathy in Cape Town: Implications for the evaluation of patients with unexplained cardiomyopathy. S Afr Med J 2011;101;xxx (this issue). TO BE COMPLETED
8. Moolman-Smook JC, Mayosi BM, Brink PA, Corfield VA. Molecular genetics of cardiomyopathy: changing times, shifting paradigms. Cardiovasc J S Afr 2003;14:145-155.
9. Mayosi BM. The UCT Department of Medicine at 90 years: Continuity and change. S Afr Med J 2010;100:548.
10. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J 1999;20:93-102.
11. Grünig E, Tasman JA, Kücherer H, Franz W, Kübler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998;31(1):186-194.
12. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992;326(2):77-82.
13. Keeling PJ, Gang Y, Smith G, et al. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J 1995;73:417-421.
14. Zachara E, Caforio AL, Carboni GP, et al. Familial aggregation of idiopathic dilated cardiomyopathy: clinical features and pedigree analysis in 14 families. Br Heart J 1993;69(2):129-135.
15. Michels VV, Driscoll DJ, Miller FA, et al. Progression of familial and non-familial dilated cardiomyopathy: long term follow up. Heart 2003;89(7):757-761.
16. Moretti M, Merlo M, Barbati G, et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail 2010;12(9):922-927.
17. Limongelli G, Pacileo G, Ancona R, et al. Clinical course and risk profile in adolescents with idiopathic dilated cardiomyopathy. Am J Cardiol 2010;105(5):716-720.
18. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52(15):1250-1260.
19. Hombach V, Merkle N, Torzewski J, et al. Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2009;30(16):2011-2018.
20. Amiya E, Tanabe K, Ikari Y, Nakajima Y, Hara K. Prolonged QRS duration and severity of mitral regurgitation are unfavorable prognostic markers of heart failure in patients with nonischemic dilated cardiomyopathy. Circ J 2006;70(1):57-62.
21. Konstam MA. Progress in heart failure management?: Lessons from the real world. Circulation 2000;102(10):1076-1078.
22. Deedwania PC. The key to unraveling the mystery of mortality in heart failure: An integrated approach. Circulation 2003;107(13):1719-1721.
23. Lee DC-S, Johnson RA, Bingham JB, et al. Heart failure in outpatients. N Engl J Med 1982;306(12):699-705.
24. Group TC-DMR, Cohn J, Hawkins M, et al. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544.
25. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347(18):1403-1411.
26. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-533.
27. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-878.